

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 5 | — | — | — | 5 |
| Hepatitis b | D006509 | — | — | — | 2 | — | — | 1 | 3 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | 2 | — | — | 1 | 3 |
| Hepatitis | D006505 | — | K75.9 | — | 2 | — | — | 1 | 3 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | 2 | — | — | 1 | 3 |
| Infections | D007239 | EFO_0000544 | — | — | 2 | — | — | — | 2 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 2 | — | — | — | 2 |
| Chronic hepatitis | D006521 | — | K73.9 | — | 1 | — | — | 1 | 2 |
| Drug common name | ELVUCITABINE |
| INN | elvucitabine |
| Description | Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Achillion Pharmaceuticals, Inc. for the treatment of HIV infection.
|
| Classification | Small molecule |
| Drug class | nucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc(=O)n([C@@H]2C=C[C@H](CO)O2)cc1F |
| PDB | — |
| CAS-ID | 181785-84-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL38700 |
| ChEBI ID | — |
| PubChem CID | 469717 |
| DrugBank | — |
| UNII ID | M09BUF90C0 (ChemIDplus, GSRS) |
